医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

BeiGene Announces

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

バイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces BRUKINSA Markets zanubrutinib

2022年06月13日

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

ヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces BRUKINSA FDA Acceptance of Supplemental New Drug in Chronic Lymphocytic Leukemia zanubrutinib

2022年02月22日

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia BeiGene Announces BRUKINSA zanubrutinib

2021年10月11日

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Approved for Treatment of Patients with Mantle Cell Lymphoma BeiGene Announces BRUKINSA zanubrutinib

2021年10月11日

BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces BRUKINSA FDA Acceptance and Priority Review in Marginal Zone Lymphoma zanubrutinib

2021年05月19日